Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan?

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group.

Genet Med. 2009 Jan;11(1):15-20. doi: 10.1097/GIM.0b013e31818efd9d.

2.

Pharmacogenetics of Gilbert's syndrome.

Strassburg CP.

Pharmacogenomics. 2008 Jun;9(6):703-15. doi: 10.2217/14622416.9.6.703. Review.

PMID:
18518849
3.

Delivery of genomic medicine for common chronic adult diseases: a systematic review.

Scheuner MT, Sieverding P, Shekelle PG.

JAMA. 2008 Mar 19;299(11):1320-34. doi: 10.1001/jama.299.11.1320. Review.

PMID:
18349093
4.

UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters.

Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL.

J Natl Cancer Inst. 2007 Sep 5;99(17):1290-5. Epub 2007 Aug 28.

PMID:
17728214
5.

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.

Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramírez J, Rudin CM, Vokes EE, Ratain MJ.

J Clin Oncol. 2004 Apr 15;22(8):1382-8. Epub 2004 Mar 8.

PMID:
15007088
6.

Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.

Ando Y, Saka H, Ando M, Sawa T, Muro K, Ueoka H, Yokoyama A, Saitoh S, Shimokata K, Hasegawa Y.

Cancer Res. 2000 Dec 15;60(24):6921-6.

7.

Supplemental Content

Support Center